SNDX Stock Price | Syndax Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Syndax Pharmaceuticals Inc • SNDX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Syndax Pharmaceuticals Inc

Ticker

SNDX

Trading on

NASDAQ

ISIN

US87164F1057

Industry

Biotechnology

Sector

Healthcare

CEO

Michael A. Metzger M.B.A.

Headquarters

730 Third Avenue, New York, NY, United States, 10017

Employees

270

Website

https://syndax.com

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Metrics

BasicAdvanced

Market cap

$1.37B

P/E ratio

EPS

-$3.60

Dividend Yield

0.00%

Beta

0.52

Forward P/E ratio

EBIDTA

$-307M

Ex dividend date

Price & volume

Market cap

$1.37B

Average daily volume

3.8M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

12.28

Price to book

11.32

Earnings

EPS

-$3.60

EPS estimate (current quarter)

-$0.71

EPS estimate (next quarter)

-$0.59

EBITDA

$-307M

Revenues (TTM)

$111M

Revenues per share (TTM)

$1.29

Technicals

Beta

0.52

52-week High

$17.87

52-week Low

$8.58

50-day moving average

$15.24

200-day moving average

$12.98

Short ratio

10.64

Short %

28.87%

Management effectiveness

ROE (TTM)

-129.32%

ROA (TTM)

-39.24%

Profit margin

-279.93%

Gross profit margin

$-133M

Operating margin

-125.19%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

267.00%

Share stats

Outstanding Shares

86.9M

Float

77.8M

Insiders %

1.28%

Institutions %

121.48%

Analyst Insights & forecasts

92% Buy

8% Hold

0% Sell

Based on information from 12 analysts.

Average price target

$38.85

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.10

-$0.23

-380.56%

Q4 • 24Missed

-$0.98

-$1.27

22.68%

Q1 • 25Beat

-$0.83

-$1.01

17.82%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$38M

$-71.8M

-189.28%

Q2 • 25

$45.9M

$-60.7M

-132.36%

Q3 • 25

20.85%

-15.49%

-30.07%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$596M

$439M

73.59%

Q2 • 25

$552M

$436M

79.08%

Q3 • 25

-7.44%

-0.54%

7.46%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-87.8M

$41.9M

$0.6M

$-87.8M

Q2 • 25

$-70.5M

$72.4M

$6.3M

$-70.7M

Q3 • 25

-19.66%

72.92%

1,039.38%

-19.51%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Syndax Pharmaceuticals Inc share?

Syndax Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc currently has 86.9M shares.

Does Syndax Pharmaceuticals Inc pay dividends?

No, Syndax Pharmaceuticals Inc doesn't pay dividends.

What is Syndax Pharmaceuticals Inc 52 week high?

Syndax Pharmaceuticals Inc 52 week high is $17.87.

What is Syndax Pharmaceuticals Inc 52 week low?

Syndax Pharmaceuticals Inc 52 week low is $8.58.

What is the 200-day moving average of Syndax Pharmaceuticals Inc?

Syndax Pharmaceuticals Inc 200-day moving average is $12.98.

Who is Syndax Pharmaceuticals Inc CEO?

The CEO of Syndax Pharmaceuticals Inc is Michael A. Metzger M.B.A..

How many employees Syndax Pharmaceuticals Inc has?

Syndax Pharmaceuticals Inc has 270 employees.

What is the market cap of Syndax Pharmaceuticals Inc?

The market cap of Syndax Pharmaceuticals Inc is $1.37B.

What is the P/E of Syndax Pharmaceuticals Inc?

The current P/E of Syndax Pharmaceuticals Inc is null.

What is the EPS of Syndax Pharmaceuticals Inc?

The EPS of Syndax Pharmaceuticals Inc is -$3.60.

What is the PEG Ratio of Syndax Pharmaceuticals Inc?

The PEG Ratio of Syndax Pharmaceuticals Inc is 0.

What do analysts say about Syndax Pharmaceuticals Inc?

According to the analysts Syndax Pharmaceuticals Inc is considered a buy.